Coughing and wheezing can leave anyone wondering whether it is asthma or bronchitis at play. Both of these respiratory issues ...
An asthma treatment that only requires patients to have two jabs a year to prevent life-threatening attacks will be available ...
On average, 10.6% of Louisiana adults reported ever being told by a health professional that they have asthma. These parishes ...
Marketed as Exdensur, the ultra-long-acting biologic is the first of its kind, requiring only two injections per year to ...
Dear Dr. Roach: In a recent column, you noted that many patients do not properly use their inhaled asthma/chronic obstructive pulmonary disease (COPD) medications, but you didn't tell us how to ...
In a recent column, you noted that many patients do not properly use their inhaled asthma/chronic obstructive pulmonary ...
Detailed price information for Jasper Therapeutics Inc. (JSPR-Q) from The Globe and Mail including charting and trades.
MedPage Today on MSN
The Promise of Biomarkers to Direct Chronic Spontaneous Urticaria Therapy
Pathophysiologic biomarkers for chronic spontaneous urticaria (CSU) are emerging, which can help better target therapies for ...
UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...
GSK plc announced the marketing authorisation of Exdensur (depemokimab) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, Exdensur is now approved in two indications: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback